We are live on ! Find out more
VTRS icon

Viatris

596 hedge funds and large institutions have $15.7B invested in Viatris in 2016 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 206 increasing their positions, 239 reducing their positions, and 86 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more call options, than puts

Call options by funds: $316M | Put options by funds: $279M

4% less funds holding

Funds holding: 622596 (-26)

14% less repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 239

18% less capital invested

Capital invested by funds: $19.3B → $15.7B (-$3.54B)

22% less first-time investments, than exits

New positions opened: 67 | Existing positions closed: 86

43% less funds holding in top 10

Funds holding in top 10: 3520 (-15)

Holders
596
Holders Change
-26
Holders Change %
-4.18%
% of All Funds
15.82%
Holding in Top 10
20
Holding in Top 10 Change
-15
Holding in Top 10 Change %
-42.86%
% of All Funds
0.53%
New
67
Increased
206
Reduced
239
Closed
86
Calls
$316M
Puts
$279M
Net Calls
+$37.6M
Net Calls Change
-$41.1M

VTRS Hedge Fund Activity: Q1 2016 in Review

596 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Viatris (VTRS) for Q1 2016, worth a combined $15.7B — down 18% from $19.3B a quarter earlier.

Sellers outnumbered buyers: 86 funds closed out of VTRS and 67 opened new positions — a net loss of 19 holders — while 239 trimmed existing stakes and 206 added.

The largest buyer was Bank of America, adding an estimated $426M. The largest seller was Goldman Sachs, cutting an estimated $233M.

  • 596 institutional investors held Viatris (VTRS) as of Q1 2016, down from 622 in Q4 2015.
  • Funds reported $15.7B of Viatris stock for Q1 2016, down 18% quarter-over-quarter.
  • 67 funds opened new Viatris positions in Q1 2016 and 86 closed out, a net change of -19 holders.
  • The largest Viatris buyer in Q1 2016 was Bank of America, an estimated $426M added.
  • The largest Viatris seller in Q1 2016 was Goldman Sachs, an estimated $233M sold.

Based on aggregated 13F filings for Q1 2016.